Venus Medtech (Hangzhou), Inc. Class H (2500) AI Stock Analysis

• Market Cap: HK$1.42B
• Dividend Yield: N/A
• Average Volume (3M): 4.74M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: -8.56%
• EPS Growth: -14.84%
• Country: HK
• Employees: 691
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.34
• Shares Outstanding: 441,010,220
• 10 Day Avg. Volume: 2,510,089
• 30 Day Avg. Volume: 4,743,059
• PEG Ratio: -0.14
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 2.11
• P/FCF Ratio: -55.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$4.00
• Price Target Upside: 24.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: HK$4.00 ▲(24.61% Upside)

The overall stock score of 50 reflects significant financial challenges, including persistent losses and weak cash flow, which are major concerns. Technical analysis provides some positive signals, but valuation remains a critical issue due to negative earnings. The absence of earnings call insights and corporate events limits additional context.

Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model

Company Description

Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.

How the Company Makes Money

Venus Medtech generates revenue primarily through the sale of its medical devices, particularly its transcatheter aortic valve products. The company has established key partnerships with hospitals and healthcare systems, enabling it to sell its products directly to medical facilities that perform cardiovascular procedures. Additionally, Venus Medtech may benefit from recurring revenue through maintenance contracts, training services for healthcare professionals, and potential licensing agreements for its proprietary technologies. The growing demand for minimally invasive procedures, along with an increasing patient population requiring cardiovascular care, further bolsters the company's revenue potential.

Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview

Summary

Venus Medtech is facing substantial financial headwinds, characterized by persistent losses and cash flow difficulties. While there are strengths such as a strong gross profit margin and a manageable debt load, the company's inability to achieve profitability and positive cash flow is a significant concern. Continued focus on cost management and revenue growth is essential to improve financial health and ensure long-term sustainability.

Income Statement

The company exhibits a challenging financial situation with consistent net losses over the years. The gross profit margin is relatively strong, indicating effective cost management, but the company is struggling with negative EBIT and EBITDA margins, reflecting significant operational challenges. Revenue growth has been inconsistent, with a decline in the most recent year, highlighting potential issues in market expansion or product demand.

Balance Sheet

The balance sheet shows a strong equity position with a manageable level of debt, as reflected by a favorable debt-to-equity ratio. However, the declining equity ratio over the years and consistent net losses pose risks to financial stability. The company has maintained a solid cash position, but the reduction in cash and equivalents suggests potential liquidity concerns if losses persist.

Cash Flow

Cash flow analysis reveals significant challenges with negative free cash flow over multiple periods, although there is a positive shift in operating cash flow in the latest year. The operating cash flow to net income ratio indicates some improvement, but the company's cash flow generation remains weak overall, raising concerns about its ability to sustain operations without additional financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	470.83M	491.37M	406.46M	415.86M	276.05M
Gross Profit	367.75M	389.20M	314.00M	324.34M	227.28M
EBITDA	-612.96M	-547.84M	-999.37M	-324.03M	-152.83M
Net Income	-714.31M	-703.75M	-1.12B	-371.39M	-182.87M
Balance Sheet
Total Assets	3.25B	4.41B	5.28B	5.11B	4.32B
Cash, Cash Equivalents and Short-Term Investments	305.70M	781.64M	1.88B	2.96B	2.75B
Total Debt	369.09M	826.19M	899.64M	70.78M	32.76M
Total Liabilities	1.04B	1.49B	1.65B	477.61M	461.19M
Stockholders Equity	2.21B	2.92B	3.61B	4.55B	3.82B
Cash Flow
Free Cash Flow	-17.82M	-872.93M	-908.23M	-602.08M	-361.05M
Operating Cash Flow	23.74M	-610.02M	-729.46M	-456.92M	-237.00M
Investing Cash Flow	-19.90M	-346.86M	-1.07B	-653.04M	-297.94M
Financing Cash Flow	-487.34M	-173.99M	635.14M	1.39B	927.75M

Venus Medtech (Hangzhou), Inc. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.21
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 3.21 is below the 20-day moving average (MA) of 3.81, below the 50-day MA of 3.82, and below the 200-day MA of 3.82, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 32.43 is Neutral, neither overbought nor oversold. The STOCH value of 5.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.

Venus Medtech (Hangzhou), Inc. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	64 Neutral	HK$2.47B	52.96	-1.28%	―	32.93%	―
2190	59 Neutral	HK$7.58B	44.75	3.23%	0.47%	35.01%	483.73%
2216	57 Neutral	HK$1.48B	-11.51	-9.03%	―	-30.60%	28.61%
2160	51 Neutral	HK$2.99B	563.64	-2.26%	―	-4.38%	―
2500	50 Neutral	HK$1.42B	―	-26.80%	―	-8.56%	-14.84%
9996	41 Neutral	HK$4.10B	-16.75	-11.17%	―	29.25%	9.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Venus Medtech (Hangzhou), Inc. Class H Corporate Events

Venus Medtech Reports Interim Financial Results Amid Revenue Decline

Venus Medtech (Hangzhou) Inc. reported its unaudited consolidated interim results for the first half of 2025, showing a decrease in revenue by 18.9% compared to the same period in 2024. Despite a reduction in losses before tax by 35.1%, the company continues to face challenges with a loss of RMB 134,772,000 for the period, highlighting ongoing financial pressures and the need for strategic adjustments to improve profitability.

The most recent analyst rating on (HK:2500) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.

Venus Medtech Schedules Board Meeting to Review Interim Results

Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for August 28, 2025, to review and approve the interim results for the first half of 2025. The meeting will also consider the recommendation of an interim dividend and address other business matters, potentially impacting the company’s financial strategy and stakeholder interests.

Venus Medtech Announces Successful AGM Resolutions

Venus Medtech (Hangzhou) Inc. announced that all resolutions proposed at its 2024 Annual General Meeting (AGM) were approved. The AGM, held on June 27, 2025, included the election of a new chairman and board members, re-appointment of auditors, and approval of the 2024 annual report and profit distribution plan. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued governance and operational stability.

Venus Medtech Announces Board Composition and Roles

Venus Medtech (Hangzhou) Inc. has announced the composition of its board of directors and their respective roles within various board committees. This update reflects the company’s commitment to strong corporate governance and strategic leadership, which is crucial for maintaining its competitive position in the medical technology sector.

Venus Medtech Enhances Governance with New Nomination Committee Terms

Venus Medtech (Hangzhou) Inc. has outlined the terms of reference for its Nomination Committee, a specialized committee under the Board of Directors. The committee, consisting of at least three directors with a majority of independent non-executive directors, is tasked with ensuring diversity and suitable qualifications in board member selection. This initiative is expected to enhance the company’s governance structure and align with its corporate strategy, potentially impacting its industry positioning by promoting a diverse and skilled leadership team.